I
Ian D. Pavord
Researcher at University of Oxford
Publications - 654
Citations - 55329
Ian D. Pavord is an academic researcher from University of Oxford. The author has contributed to research in topics: Asthma & Sputum. The author has an hindex of 108, co-authored 575 publications receiving 47691 citations. Previous affiliations of Ian D. Pavord include John Radcliffe Hospital & University of Warwick.
Papers
More filters
Journal ArticleDOI
Using fractional exhaled nitric oxide to guide step down treatment decisions in patients with asthma: a systematic review and individual patient data meta-analysis.
Kay Wang,Jan Y Verbakel,Jason Oke,Alexander Fleming-Nouri,Josh Brewin,Nia Roberts,Norihiro Harada,Ryo Atsuta,Kazuhisa Takahashi,Kazutaka Mori,Tomoyuki Fujisawa,Toshihiro Shirai,Tomotaka Kawayama,Hiromasa Inoue,Stephen C. Lazarus,Stanley J. Szefler,Fernando J. Martinez,Dominick E. Shaw,Ian D. Pavord,Mike Thomas +19 more
TL;DR: In nonsmoking patients with mild-to-moderate well-controlled asthma, stepping down treatment when FENO is <50 ppb reduces prescribing of inhaled corticosteroids without increasing exacerbations.
Journal ArticleDOI
A new approach to the classification and management of airways diseases: identification of treatable traits.
TL;DR: A new mechanism-based approach where the emphasis is on identification of key causal mechanisms and targeted intervention with treatment based on possession of the relevant mechanism rather than an arbitrary label is suggested.
Journal Article
What is the minimal important difference for the Leicester Cough Questionnaire
Journal ArticleDOI
The burden of exacerbations in mild asthma: a systematic review.
J. Mark FitzGerald,Peter J. Barnes,Bradley E. Chipps,Christine Jenkins,Paul M. O'Byrne,Ian D. Pavord,Helen K. Reddel +6 more
TL;DR: The main outcomes were the definitions of mild asthma and exacerbations, baseline exacerbation rates and exacerbation data for placebo recipients in prospective studies, and the need for standardised definitions of Mild asthma and of exacerbations to progress further research.
Journal ArticleDOI
Unmet Needs in Severe Asthma Subtyping and Precision Medicine Trials. Bridging Clinical and Patient Perspectives
Salman Siddiqui,Loren C. Denlinger,Stephen J. Fowler,Praveen Akuthota,Dominick E. Shaw,Liam G Heaney,Louise Brown,Mario Castro,Tonya A. Winders,Monica Kraft,Scott Wagers,Michael C. Peters,Ian D. Pavord,Samantha Walker,Nizar N. Jarjour +14 more
TL;DR: Targeting airway smooth muscle dysfunction, airway mucous, type-17 immunity and airway dysbiosis, may represent novel therapeutic approaches for severe asthma in the future, despite the fact that the biomarkers for these subtypes of severe asthma are underdeveloped.